Search

Your search keyword '"Mesia R"' showing total 255 results

Search Constraints

Start Over You searched for: Author "Mesia R" Remove constraint Author: "Mesia R"
255 results on '"Mesia R"'

Search Results

2. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

16. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

17. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

18. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

19. SEOM-TTCC clinical guideline in nasopharynx cancer (2021)

20. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

26. 1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)

29. Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion

31. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

32. 2220P MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma

35. Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients

37. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment

43. PO-0815: Validation of a Prognostic Model for Predicting Larynx Preservation Outcome in Catalan Population.

44. 318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

45. 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

46. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

48. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer

49. SUN-PO112: Nutritional and Body Composition Changes During Radical Treatment for Locally Advanced Head and Neck Cancer (LA-HNC) Patients

50. PD-029 Phase II trial: melatonin oral gel for prevention of mucositis in oropharynx and oral cavity tumors

Catalog

Books, media, physical & digital resources